Skip to main content

Advertisement

SpringerLink
Log in

The importance of personalized medicine in urological cancers

  • Review article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

A better understanding of key regulatory pathways involved in cancers has led to the development of molecularly targeted therapies. Molecular profiling based on genomics, proteomics, and metabolomics in tumors provides clinicians with the necessary information to maintain a personalized therapeutic regimen according to the patient’s needs. for example, androgen deprivation therapy (ADT) for advanced prostate cancer is one of the earliest forms of targeted therapy and has remained a choice of treatment by physicians. Unfortunately, most patients will eventually become non-responsive to ADT and succumb to the disease. Since the emergence of ADT, the understanding of androgen receptor (AR) signaling and mechanisms driving the resistance to ADT has been significantly improved. Inactivation of the PTEN gene is a common occurrence in prostate cancers and is associated with metastatic potential, androgen independence, and poor prognosis. Several studies over personalized medicine for muscle-invasive and metastatic bladder cancer discussed potential molecular biomarkers which are currently under investigation and based on the excision repair cross-complementing group 1 (ERCC1) gene and its role in tumor development and therapeutic resistance to cytotoxic DNA-damaging chemotherapy and ionizing radiation. In this review, we consider personalized medicine for four urological cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Offit K. Personalized medicine: new genomics, old lessons. Hum Genet. 2011;130(1):3–14.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomedical reports. 2017;7(1):3–5.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018;109(6):952–63.

    Article  PubMed  PubMed Central  Google Scholar 

  4. van de Merbel AF, van der Horst G, van der Pluijm G. Patient-derived tumour models for personalized therapeutics in urological cancers. Nat Rev Urol. 2020(10):1–3.

  5. Eich M-L, Dyrskjøt L, Netto GJ. Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Arch. 2017;471(2):271–80.

    Article  PubMed  Google Scholar 

  6. Aghamir SMK, Shirazi MN, Khatami F. A systematic review of circulating tumor cells in renal cell Carcinoma. 2021.

  7. Alvarez-Cubero M, Martinez-Gonzalez L, Robles-Fernandez I, Martinez-Herrera J, Garcia-Rodriguez G, Pascual-Geler M, et al. Somatic mutations in prostate cancer: closer to personalized medicine. Mol Diagn Ther. 2017;21(2):167–78.

    Article  CAS  PubMed  Google Scholar 

  8. D’Amico AV, Cote K, Loffredo M, Renshaw AA, Chen M-H. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol. 2003;169(4):1320–4.

    Article  PubMed  Google Scholar 

  9. Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer. 2005;104(5):891–905.

    Article  PubMed  Google Scholar 

  10. D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M-H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21(11):2163–72.

    Article  PubMed  Google Scholar 

  11. Saadati M, Tamehri S, Kamali MP, Taheri D. Phosphatase and tensin gene association with features of aggressive prostate cancer. 2021.

  12. King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84(1):104–11.

    Article  PubMed  Google Scholar 

  13. Morgan S, Waldron T, Eapen L, Mayhew L, Winquist E, Lukka H, et al. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: guideline recommendations. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]: Centre for Reviews and Dissemination (UK). 2008.

  14. Mirzaei A, Khatami F, Ebrahimi M, Mousavibahar S, Narouie B. The Effect of herbal extracts on the treatment and prevention of prostate cancer: a literature review. Transl Res Urol. 2019;1(2):67–73.

    Google Scholar 

  15. Attard G, Sarker D, Reid A, Molife R, Parker C, De Bono J. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer. 2006;95(7):767–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mukherji D, Eichholz A, De Bono JS. Management of metastatic castration-resistant prostate cancer. Drugs. 2012;72(8):1011–28.

    Article  CAS  PubMed  Google Scholar 

  17. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15(5):559–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008;68(10):3584–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Attard G, Ang JE, Olmos D, de Bono JS. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. J Clin Pathol. 2008;61(8):891–6.

    Article  CAS  PubMed  Google Scholar 

  21. Minner S, Gärtner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, et al. Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol. 2013;26(1):106–16.

    Article  CAS  PubMed  Google Scholar 

  22. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Billis A. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. Int Braz J Urol. 2011;37(1):122–3.

    Article  Google Scholar 

  24. Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010;70(13):5207–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol. 2010;23(11):1492–8.

    Article  PubMed  Google Scholar 

  26. Zadeh SST, Taheri D, Shivarani S, Khatami F, Kazemi R. Liquid biopsy in prostate cancer diagnosis and prognosis: a narrative review.

  27. Van der Kwast TH, Roobol MJ. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol. 2013;10(8):473.

    Article  PubMed  Google Scholar 

  28. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS)≤ 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012;36(9):1346.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Karimaei S, Reis LO. Cytotoxicity and apoptotic effect of nisin as an effective bacteriocin on the cancer cells. Transl Res Urol. 2020;2(2).

  30. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 2013;5(169):169ra10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res. 2006;12(20):6094–9.

    Article  CAS  PubMed  Google Scholar 

  32. Deeken J, Cormier T, Price D, Sissung T, Steinberg S, Tran K, et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 2010;10(3):191–9.

    Article  CAS  PubMed  Google Scholar 

  33. Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, et al. Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. Clin Genitourin Cancer. 2013;11(3):229–37.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, et al. Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer. 2014;120(24):3923–31.

    Article  CAS  PubMed  Google Scholar 

  35. Li P, Zhang X, Deng X, Tao J, Qin C, Yang X, et al. Pharmacogenetic association between XRCC1 polymorphisms and improved outcomes in bladder cancer patients following intravesical instillation of epirubicin. Int J Clin Exp Med. 2015;8(7):11167.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011;29(17):2391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Sowalsky AG, Ye H, Bubley GJ, Balk SP. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res. 2013;73(3):1050–5.

    Article  CAS  PubMed  Google Scholar 

  38. Khatami F, Aghamir SMK, Salmaninejad A, Shivarani S, Khorrami MH. Biomarkers for Prostate Cancer Diagnosis from Genetic Perspectives. Transl Res Urol. 2020;2(2):51–8.

    Google Scholar 

  39. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153(3):666–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kovtun IV, Cheville JC, Murphy SJ, Johnson SH, Zarei S, Kosari F, et al. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res. 2013;73(11):3275–84.

    Article  CAS  PubMed  Google Scholar 

  41. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P, Michel MS. Identification of metastasis-associated genes inprostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res. 2005;25(1A):183–91.

  42. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sañudo A, Dall’Oglio MF, et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol. 2011;185(3):1118–22.

    Article  CAS  PubMed  Google Scholar 

  43. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 2010;127(2):394–403.

    CAS  PubMed  Google Scholar 

  44. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression–based predictors for breast cancer. N Engl J Med. 2006;355(6):560–9.

    Article  CAS  PubMed  Google Scholar 

  45. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 2002;13(6):1977–2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Cuzick J, Berney D, Fisher G, Mesher D, Møller H, Reid J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1095–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31(11):1428–34.

    Article  CAS  PubMed  Google Scholar 

  49. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE. 2013;8(6):e66855.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Wu C-L, Schroeder BE, Ma X-J, Cutie CJ, Wu S, Salunga R, et al. Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci. 2013;110(15):6121–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470(7333):214–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, et al. Genome-wide DNA methylation events in TMPRSS2–ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2012;2(11):1024–35.

    Article  PubMed  CAS  Google Scholar 

  53. Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, et al. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res. 2012;18(10):2896–904.

    Article  CAS  PubMed  Google Scholar 

  54. Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T, et al. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin Cancer Res. 2013;19(13):3450–61.

    Article  CAS  PubMed  Google Scholar 

  55. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Flaig TW, Theodorescu D. Bladder cancer in 2011: the dawn of personalized medicine. Nat Rev Urol. 2011;9(2):65–6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Shah JB, McConkey DJ, Dinney CP. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res. 2011;17(9):2608–12.

    Article  PubMed  Google Scholar 

  58. Mashhadi R, Taheri D, Mousavibahar SH, Aghaii M, Shabestari AN, Ebrahimi M, et al. Association of Microbiota and overactive bladder: A mini literature review. Transl Res Urol. 2019;1(2):66–72.

    Google Scholar 

  59. Matulay JT, Kamat AM. Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Res. 2018;7.

  60. Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, et al. The route to personalized medicine in bladder cancer: where do we stand? Target Oncol. 2015;10(3):325–36.

    Article  PubMed  Google Scholar 

  61. Ousati-Ashtiani Z, Tavakkoly-Bazzaz J, Sa S, Pourmand MR, Mansouri F, Mashahdi R, et al. Differential expression of FGFRs signaling pathway components in bladder cancer: a step toward personalized medicine. Balkan J Med Genet. 2017;20(2):75–82.

    Article  PubMed Central  CAS  Google Scholar 

  62. Cooley LF, McLaughlin KA, Meeks JJ. Genomic and therapeutic landscape of non-muscle-invasive bladder cancer. Urol Clin North Am. 2020;47(1):35–46.

    Article  PubMed  Google Scholar 

  63. Connaughton DM, Hildebrandt F. Personalized medicine in chronic kidney disease by detection of monogenic mutations. Nephrol Dial Transplant. 2020;35(3):390–7.

    Article  CAS  PubMed  Google Scholar 

  64. Palumbo P, Antona V, Palumbo O, Piccione M, Nardello R, Fontana A, et al. Variable phenotype in 17q12 microdeletions: clinical and molecular characterization of a new case. Gene. 2014;538(2):373–8.

    Article  CAS  PubMed  Google Scholar 

  65. Chen Y-Z, Qing G, Zhao X-Z, Chen Y-Z, Bennett CL, Xiong X-S, et al. Systematic review ofTCF2anomalies in renal cysts and diabetes syndrome/maturity onset diabetes of the young type 5. Chin Med J. 2010;123(22):3326–33.

    CAS  PubMed  Google Scholar 

  66. Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol. 2016;12(3):133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Brown KD, Campbell C, Roberts GV. Precision medicine in kidney disease: the patient’s view. Nat Rev Nephrol. 2020;16(11):625–7.

    Article  PubMed  Google Scholar 

  68. Precision medicine in nephrology. Nat Rev Nephrol. 2020;16(11):615.

  69. Leão R, Ahmad AE, Hamilton RJ. Testicular cancer biomarkers: a role for precision medicine in testicular cancer. Clin Genitourin Cancer. 2019;17(1):e176–83.

    Article  PubMed  Google Scholar 

  70. Idrees MT, Ulbright TM, Oliva E, Young RH, Montironi R, Egevad L, et al. The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology. 2017;70(4):513–21.

    Article  PubMed  Google Scholar 

  71. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28(20):3388–404.

    Article  CAS  PubMed  Google Scholar 

  72. Neumann A, Keller T, Jocham D, Doehn CJAU. Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer. Aktuelle Urol. 2011;42(5):311–5.

    Article  CAS  PubMed  Google Scholar 

  73. Lin SY, Linehan JA, Wilson TG, Hoon DS. Emerging utility of urinary cell-free nucleic acid biomarkers for prostate, bladder, and renal cancers. Eur Urol Focus. 2017;3(2–3):265–72.

    Article  PubMed  Google Scholar 

  74. Ellinger J, Wittkamp V, Albers P, Perabo FG, Mueller SC, von Ruecker A, et al. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol. 2009;181(1):363–71.

    Article  CAS  PubMed  Google Scholar 

  75. Voorhoeve PM, Le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124(6):1169–81.

    Article  CAS  PubMed  Google Scholar 

  76. Oldenburg J, Fosså SDJNRU. Towards personalized medicine—are we there yet? 2014;11(2):68–9.

  77. Horwich A, Dearnaley D, Sohaib A, Pennert K, Huddart RA. Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann Oncol. 2013;24(8):2104–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Special thanks to the Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Author information

Authors and Affiliations

  1. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Fatemeh Khatami, Fateme Guitynavard, Samira Karimaee, Saeyed Saeed Tamehri Zadeh, Keykavos Gholami, Seyed Ariana Feiz-Abadi & Seyed Mohammad Kazem Aghamir

  2. Personalized Medicine Research Center, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Mandana Hassanzad

  3. Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

    Mandana Hassanzad

  4. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Shekoufeh Nikfar

  5. Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    AhmadReza Rezaeian

  6. Iran University of Medical Sciences, Tehran, Iran

    Fatemeh Jahanshahi

Authors
  1. Fatemeh Khatami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mandana Hassanzad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shekoufeh Nikfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fateme Guitynavard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samira Karimaee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Saeyed Saeed Tamehri Zadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keykavos Gholami
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. AhmadReza Rezaeian
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Seyed Ariana Feiz-Abadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fatemeh Jahanshahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Seyed Mohammad Kazem Aghamir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seyed Mohammad Kazem Aghamir.

Ethics declarations

Conflict of interest

All authors claim that there is not any conflict of interest for this publication.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Fatemeh Khatami and Mandana Hassanzad are dual first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khatami, F., Hassanzad, M., Nikfar, S. et al. The importance of personalized medicine in urological cancers. J Diabetes Metab Disord 21, 841–852 (2022). https://doi.org/10.1007/s40200-021-00824-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-021-00824-0

Keywords

Search

Navigation